LINDSAY LEHECHKA: Open Payments
NPI 1942833256 · OVERLAND PARK, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$602 in 33 payments from 15 companies in 2025. Trend: 2023 $881 · 2024 $877 · 2025 $602
Food & beverage: $602
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $184 |
| Novo Nordisk Inc | 2 | $114 |
| Lilly USA, LLC | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Forte Bio-Pharma LLC | 2 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Amgen Inc. | 1 | $19 |
Products named: Ozempic, QULIPTA, VRAYLAR, MOUNJARO, UBRELVY, AIRSUPRA, PROLATE, Yorvipath.
Industry payments across KS — which companies pay providers there.
